Dr. Dilawari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
FDA White Oak Campus
10903 New Hampshire Ave
Silver Spring, MD 20993- Is this information wrong?
Summary
- Dr. Asma Dilawari is a medical oncologist and Clinical Reviewer in the Division of Oncology 1 at the FDA.
She received her medical degree from University of Tennessee Health Science Center College of Medicine, did her internal medicine training at George Washington University, and her Hematology/ Oncology fellowship at NYU/Bellevue Medical Center. She moved to Washington DC in 2013 and was on the faculty at Georgetown Lombardi Cancer Center for 9 years before joining the FDA. She specializes in breast cancer and her interests include integrative medicine, cancer survivorship, and health disparities. She completed her medical acupuncture training in 2022 and serves on several committees including Project Equity and Project Silver at the FDA. She has more than 20 publications and over 250 citings.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2006
George Washington UniversityResidency, Internal Medicine, 2001 - 2004
University of Tennessee Health Science Center College of MedicineClass of 2001
Certifications & Licensure
MD State Medical License 2013 - 2024
DC State Medical License 2013 - 2024
NY State Medical License 2005 - 2014
TN State Medical License 2008 - 2012
VA State Medical License 2004 - 2006
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Publications & Presentations
PubMed
- 8 citationsFDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H Fiero, Ankit Shah, Salaheldin S Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K Ricks, Ra...> ;Clinical Cancer Research. 2023 Oct 2
- 18 citationsUS Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Ca...Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist, William F Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Shenghui Ta...> ;Journal of Clinical Oncology. 2023 Apr 10
- 4 citationsHighlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development.Elizabeth S Duke, Michael J Fusco, Patrick DeMoss, Asma Dilawari, Gulsum E Pamuk, Jessica Boehmer, Bronwyn Mixter, Kirsten B Goldberg, Paul Kluetz, Richard Pazdur> ;Cancer Discovery. 2022 Dec 2
- Join now to see all
Press Mentions
New Study Reveals Startling Results for Cancer Patients Who Opt for Natural RemediesJuly 19th, 2018
It’s Time to Integrate Complementary Medicine Discussions into Oncology CareNovember 9th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
